[go: up one dir, main page]

AU5468499A - 3-methylidenyl-2-indolinone modulators of protein kinase - Google Patents

3-methylidenyl-2-indolinone modulators of protein kinase

Info

Publication number
AU5468499A
AU5468499A AU54684/99A AU5468499A AU5468499A AU 5468499 A AU5468499 A AU 5468499A AU 54684/99 A AU54684/99 A AU 54684/99A AU 5468499 A AU5468499 A AU 5468499A AU 5468499 A AU5468499 A AU 5468499A
Authority
AU
Australia
Prior art keywords
methylidenyl
indolinone
modulators
protein kinase
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU54684/99A
Inventor
Congxin Liang
Todd Anthony Miller
Asaad Nematalla
Anh Thi Nguyen
Li Sun
Peng Cho Tang
Ngoc My Tran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of AU5468499A publication Critical patent/AU5468499A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU54684/99A 1998-08-04 1999-08-04 3-methylidenyl-2-indolinone modulators of protein kinase Abandoned AU5468499A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US12925698A 1998-08-04 1998-08-04
US09129256 1998-08-04
US9547098P 1998-08-05 1998-08-05
US60095470 1998-08-05
US10217898P 1998-09-28 1998-09-28
US60102178 1998-09-28
US11610799P 1999-01-15 1999-01-15
US60116107 1999-01-15
PCT/US1999/017845 WO2000008202A2 (en) 1998-08-04 1999-08-04 3-methylidenyl-2-indolinone modulators of protein kinase

Publications (1)

Publication Number Publication Date
AU5468499A true AU5468499A (en) 2000-02-28

Family

ID=27492796

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54684/99A Abandoned AU5468499A (en) 1998-08-04 1999-08-04 3-methylidenyl-2-indolinone modulators of protein kinase

Country Status (4)

Country Link
JP (1) JP2002522452A (en)
AU (1) AU5468499A (en)
CA (1) CA2383623A1 (en)
WO (1) WO2000008202A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
BR9916324A (en) 1998-12-17 2001-10-02 Hoffmann La Roche 4,5-pyrazinoxindoles as protein kinase inhibitors
BR9916223A (en) 1998-12-17 2001-09-04 Hoffmann La Roche 4-aryloxindols as inhibitors of jnk protein kinases
JP2002532492A (en) 1998-12-17 2002-10-02 エフ.ホフマン−ラ ロシュ アーゲー 4-Alkenyl (and alkynyl) oxidols as inhibitors of cyclin-dependent kinases, especially CDK2
US6153634A (en) * 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
EP1233943B1 (en) * 1999-11-24 2011-06-29 Sugen, Inc. Ionizable indolinone derivatives and their use as ptk ligands
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
PT1255752E (en) 2000-02-15 2007-10-17 Pharmacia & Upjohn Co Llc Pyrrole substituted 2-indolinone protein kinase inhibitors
US20020028828A1 (en) 2000-05-02 2002-03-07 Chung-Chen Wei (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
MY128450A (en) * 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
EP1294688A2 (en) 2000-06-02 2003-03-26 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
WO2002055517A2 (en) 2000-12-20 2002-07-18 Jingrong Cui 4-(hetero)aryl substituted indolinones
AR042586A1 (en) 2001-02-15 2005-06-29 Sugen Inc 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE
WO2002070478A1 (en) 2001-03-06 2002-09-12 Astrazeneca Ab Indolone derivatives having vascular-damaging activity
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
WO2002081466A1 (en) 2001-04-09 2002-10-17 Sugen, Inc. Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2448076A1 (en) * 2001-05-24 2002-11-28 Masahiko Hayakawa 3-quinoline-2-(1h)-ylideneindolin-2-one derivatives
PE20030062A1 (en) 2001-05-30 2003-02-08 Sugen Inc ARALKYLSULFONIL-3- (PYRROL-2-ILMETILIDEN) -2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS
US6777417B2 (en) 2001-09-10 2004-08-17 Sugen, Inc. 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors
ES2275021T3 (en) 2001-09-27 2007-06-01 Smithkline Beecham Corporation DERIVATIVES OF AZOXOINDOL AS INHIBITORS OF TRK PROTEIN KINASE FOR THE TREATMENT OF CANCER AND CHRONIC PAIN.
AU2003284572A1 (en) * 2002-11-22 2004-06-18 Yamanouchi Pharmaceutical Co., Ltd. 2-oxoindoline derivatives
JP4879492B2 (en) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド Kinase inhibitors for the treatment of diseases
US7517697B2 (en) * 2003-02-05 2009-04-14 Applied Biosystems, Llc Compositions and methods for preserving RNA in biological samples
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
GT200500321A (en) 2004-11-09 2006-09-04 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASE.
EP1883403A4 (en) * 2005-04-29 2011-02-16 Univ Ohio State Res Found SPECIFIC INHIBITORS AGAINST TYROSINE OF KERATINOCYTE GROWTH FACTOR RECEPTOR USEFUL IN PREVENTING CANCER METASTASES
WO2009030270A1 (en) * 2007-09-03 2009-03-12 Novartis Ag Dihydroindole derivatives useful in parkinson's disease
CN101970426A (en) * 2007-12-21 2011-02-09 大学健康网络 Indazolyl, benzimidazolyl, and benzotriazolyl-substituted indolinone derivatives as useful kinase inhibitors in cancer therapy
US8481525B2 (en) 2009-04-06 2013-07-09 University Of Health Network Kinase inhibitors and method of treating cancer with same
FR2948940B1 (en) * 2009-08-04 2011-07-22 Servier Lab NOVEL DIHYDROINDOLONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
KR101782668B1 (en) 2010-04-06 2017-09-27 유니버시티 헬스 네트워크 Kinase inhibitors and method of treating cancer with same
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
WO2012142029A2 (en) * 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
MX2015003330A (en) 2012-09-13 2015-06-05 Hoffmann La Roche 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders.
US9296730B2 (en) 2012-10-26 2016-03-29 Regents Of The University Of Minnesota Aurora kinase inhibitors
MX357763B (en) 2013-10-18 2018-07-23 Univ Health Network Treatment for pancreatic cancer.
CA3004595A1 (en) * 2015-11-12 2017-05-18 Lg Chem, Ltd. Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
US10487054B2 (en) 2017-04-21 2019-11-26 Regents Of The University Of Minnesota Therapeutic compounds
PH12021550742A1 (en) * 2018-10-05 2023-02-27 Ichnos Sciences S A Indolinone compounds for use as map4k1 inhibitors
GR1010103B (en) * 2020-07-02 2021-10-18 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, 3-indol-2-ylmethylidene-indolin-2-ones as autotaxin inhibitors
WO2022006412A2 (en) * 2020-07-02 2022-01-06 The Regents Of The University Of Colorado, A Body Corporate Conjugates of ampk inhibitors and protac degraders and related uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
FR2678911A1 (en) * 1991-07-10 1993-01-15 Prospection & Inventions TUBULAR CARTRIDGE FOR STORAGE AND APPLICATION OF A NON-SOLID PRODUCT AND TRAINING AND PUSHING ASSEMBLY FOR THE CARTRIDGE.
GB9115160D0 (en) * 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
FR2694004B1 (en) * 1992-07-21 1994-08-26 Adir News 3- (Hydroxybenzylidenyl) -indoline-2-ones and 3- (hydroxybenzylidenyl) -indoline-2-thiones, methods of preparation, and pharmaceutical compositions containing them.
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds

Also Published As

Publication number Publication date
JP2002522452A (en) 2002-07-23
WO2000008202A3 (en) 2000-05-18
WO2000008202A2 (en) 2000-02-17
CA2383623A1 (en) 2000-02-17
WO2000008202A9 (en) 2000-07-27

Similar Documents

Publication Publication Date Title
AU5468499A (en) 3-methylidenyl-2-indolinone modulators of protein kinase
AU6411698A (en) Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
AU5324996A (en) Protein kinase c inhibitors
AU8681798A (en) Imidazoquinoxaline protein tyrosine kinase inhibitors
AU5173400A (en) Protein kinases
AU1371999A (en) Benzothiazole protein tyrosine kinase inhibitors
AU8681698A (en) Imidazoquinoxaline protein tyrosine kinase inhibitors
AU2434199A (en) Protein
AU7282998A (en) Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds
AU8154798A (en) Disease associated protein kinases
AU6882598A (en) Protein kinase inhibitor
AU7829700A (en) Protein phosphatase and kinase proteins
AU6142899A (en) Human transferase proteins
AU4261197A (en) Human protein kinases
AU2113899A (en) Human protein kinase molecules
AU4686299A (en) Nek-related and bub1-related protein kinases
AU2241699A (en) Expression of proteolytically-sensitive peptides
AU2591299A (en) Human protein kinase c inhibitor
AU2538899A (en) Protein kinase c
AU5131699A (en) Cryogranulation of activated protein c
AU6000698A (en) Proteins
AU4684099A (en) Oligonucleotides for enhanced modulation of protein kinase expression
AU6275098A (en) Novel h-rev 107-like protein
AU8102498A (en) Preparation of diaryl-benzopyrans
AU7954998A (en) Cyclin related proteins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase